News
Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share
Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share The conversion price represents a premium to market June 28, 2021 09:25 ET http://schema.org/Organization">| Source: Cosmos Holdings   CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, is pleased to announce that Mr. Greg Siokas, Chief Executive Officer, has reduced the debt of the ...
Cosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business
Cosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business May 18, 2021 09:00 ET http://schema.org/Organization">| Source: Cosmos Holdings   CHICAGO, May 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the first quarter ended March 31, 2021. Greg Siokas, Chief Executive Officer ...
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon UK
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon UK Marks First Step in Global E-Commerce Strategy; Reaffirms Plans to Enter New European and Global Markets in 2021 April 27, 2021 09:15 ET http://schema.org/Organization">| Source: Cosmos Holdings CHICAGO, April 27, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company”) (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today announced that the Company’s subsidiary, Decahedron Ltd, a UK-based ...
Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020
CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020. 2020 Financial Highlights: Revenue for 2020 increased 40% to $55.4 Million, versus $39.7 for the same period last year Gross profit for 2020 increased 120% to $8.1 million, versus $3.7 ...
Cosmos Holdings Launches Proprietary King Eros and Queen Venus Supplements for Enhanced Libido
Sky Premium Life King Eros and Queen Venus Supplements     Sky Premium Life King Eros and Queen Venus Supplements Sky Premium Life King Eros and Queen Venus Supplements King Eros supplement formula developed to improve sexual health and men’s libido   Queens Venus is a complete nutritional supplement for women designed to increase energy and libido CHICAGO, April 14, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, ...
Photo
David E. Gutierrez
Head of PR, IR
and Corporate Development

Join our mailing list to stay up to date.

Cosmos-logo